



# Annual Report

2022-2023



Consumer Healthcare  
Products Australia

Advancing Responsible Self-Care

# CHP Australia Purpose & Mission

Our members are manufacturers and distributors of consumer healthcare products, which includes nonprescription medicines and consumer facing medical devices. CHP Australia also represents businesses that support our industry.

These include advertising agencies and PR firms as well as legal, statistical and regulatory consultancy companies and individuals.

---

## Purpose

Advance consumer health through responsible self-care.

---

## Mission

To enhance the health and well-being of Australians through access to evidence-based healthcare products and solutions.







# CHP Australia Strategic Goals 2021–2023

CHP Australia's 3 year strategic plan is structured around 4 key pillars for action:

1

SHAPE  
GOVERNMENT  
& REGULATORY  
POLICY

2

ADVANCE  
SELF-CARE

3

ENHANCE  
SUPPLY  
CHAIN  
RESILIENCE

4

FUTURE-  
PROOF THE  
MEMBERSHIP  
MODEL



6	Chair and CEO's Message
7	AdCheck Service - Launch of TVC classification
	<b>VOICE OF INDUSTRY</b>
8	Setting the Industry Agenda
11	Leading on Issues Management
	<b>REGULATORY ENVIRONMENT</b>
12	Driving Regulatory Reform
16	<b>SUSTAINABILITY</b>
17	<b>PARTNERSHIPS</b>
	<b>CHP AUSTRALIA</b>
18	Board
20	Subcommittees and Working Groups
21	Your Support Team
22	Events
23	Contact Details

## Chair and CEO's Message

Before we reflect on the opportunities and challenges the first year of the post-pandemic era presented, we would like to welcome the members who joined this year – Organon, Bread Agency, Ian Adams and Associates, Pharma to Market, Precisions Public Affairs, and Ward 6.

The TGA's announcement of a review into paracetamol, in response to reports of intentional self-harm, triggered a comprehensive and resource intensive response by CHP Australia. The regulatory team engaged with members as well as non-members in the category to ensure a comprehensive and aligned industry response. The outcome of the review was measured, balanced and appropriate. We would like to acknowledge the TGA for what we regard as a model for public consultation.

Sustainability and the impact of our industry on the environment is a key priority for CHP Australia. The areas of focus are packaging, medicines in the environment and the energy footprint. A continuous objective for us has been supporting our members to meet the Australian Packaging Covenant Organisation's (APCO) 2025 National Packaging Targets, and working to develop industry-led solutions for challenging packaging types, such as blister packs.

In April 2023, we held a roundtable with the wider industry involved in the life cycle of blister packs, to learn about the process of establishing a product stewardship program, and garner wider industry perspectives and understanding of the issue. All attendees agreed that blister pack recyclability is incredibly important and needs to be addressed through a wider industry working group.

The adoption of self-care in national health policy remains a strategic priority for CHP Australia and we've been working at Government as well as grassroots level. CHP Australia is represented on the board of the Australian Self-Care Alliance (the Alliance). The Alliance firmly established its credentials as an important voice in the self-care policy debate when Government acknowledged the proposals put forward in its first pre-budget submission.

The Alliance is the primary vehicle pushing for the development and implementation of the nine policy focus areas identified in the [Self-Care Policy Blueprint](#). Two of the areas have gained government attention. The development of a National Health Literacy Strategy commenced under the previous government and another round of public consultation is expected before the end of 2023. The Government recently announced public consultation on the development of a National Consumer Engagement Strategy for Health and Wellbeing.

At grassroots (consumer) level we entered into the next major phase of our longstanding collaboration with Life Education. The Board agreed to support the development and rollout of a vaping education campaign targeting year 5 and 6 students. Our much-valued partnership with Sydney North Health Network is again bearing fruit through the GPs in High Schools program.

Our Strategic Self-Care Research Program continued to be rolled out with the commencement of a 2 year project to develop a model to enhance consumer self-care behaviour in the community pharmacy setting using digital information. This

projected is conducted in partnership between Sydney North Health Network, community pharmacies and consumers.

One of the goals of the 2021-2023 strategic plan was to future proof the CHP Australia membership model. This entailed a review of the value proposition to ensure the services we provide meet member expectations and to examine alternative of sources revenue. As part of the review an international benchmarking exercise was conducted to determine how we compare to our international peers. The report provided very useful insights and made a range of recommendations to broaden the revenue base.

We again played our part on the international front, supporting our world body, the Global Self-Care Federation (GSCF). The second edition of the Self-Care Readiness Index (SCRI) was launched in Cape Town, South Africa, in October 2022.

The SCRI is supported by the World Health Organisation (WHO) and forms part of the current working plan between the two bodies. It is a first-of-its-kind research and policy initiative that explores critical enablers of self-care across various health systems around the world. It aims to support a more sustainable design of healthcare systems and build a foundation for action-oriented initiatives at all levels. Australia was amongst the 10 countries surveyed in SCRI 2.0 and the report notes that Australia is a global leader in consumer and patient empowerment.

The AdCheck advertising compliance service is going from strength to strength and has experienced significant growth throughout its third year of operation. Increasing uptake and positive customer feedback, has led to the expansion of the team of expert advisors, and the addition of TVC classifications to its comprehensive range of services.


We hosted another highly successful Stakeholder Summit in February 2023 in Canberra. The event was well-attended and well-received by the Members of Parliament and their staff, the TGA leadership, and other non-parliamentary stakeholders who took the time to join us.

We would like to thank our members for their support over the past year. We are fully aware of the significant investment, both financial and personal engagement in committee activities, which are crucial in ensuring effective representation of individual members and the industry more broadly.

We also thank the CHP Australia Board for its guidance and support for the secretariat team. And finally, a word of sincere thanks to the secretariat team for their dedication and commitment.



*Phil Lynch*  
**Phil Lynch**  
Chair



*Deon Schoombie*  
**Deon Schoombie**  
Chief Executive Officer



# AdCheck Service- Launch of TVC classification

The last 3 years since AdCheck’s launch has seen the service go from strength to strength. Feedback from users has been overwhelmingly positive.

Several clients have embraced the TVC classification service, appreciating the one-stop-shop for both TGAC certification and TVC classification. Since the inception of the service, 55 classifications have been completed, and feedback from both the clients themselves and the TV networks has been excellent.

For more information please visit [adcheck.com.au](http://adcheck.com.au)



**200+** companies using AdCheck



**8000+**  
pieces of advertising reviewed since launch, including TV, radio, in-store, online, print



Ran multiple training workshops to build industry expertise on the TGAC (Therapeutic Goods Advertising Code)

## Digital & Social Media Guidelines

CHP Australia provides detailed guidelines to assist advertisers



**AdCheck**

### Highlights of the AdCheck Service Include:

**Experience** – At CHP Australia we have over 25 years of experience performing detailed advertising compliance checks and are well known as the benchmark regulatory experts in Australia for therapeutic goods. Our AdCheck team has in-depth expertise on the intricacies of the Therapeutic Goods Act, Regulations and Advertising Code, which is arguably the most detailed, complex legislation for consumer goods. We stay up to date on any changes and as the industry body representing therapeutic goods we have strong relationships with the TGA and the Department of Health and Aged Care.

**Coaching and compliance training** – Our aim is to assist you to reach compliance on any given ad. We provide coaching and advice on how to reach compliance for an ad; we don’t just provide an ‘it needs fixing’ response.

**Unique AdCheck verification number** – CHP Australia is well known and respected throughout industry for its expertise in compliance for therapeutic goods; a CHP Australia AdCheck number assigned to compliant ads represents quality and assurance and can be verified upon request.

**Support managing complaints** – As a client of CHP Australia, if a complaint arises, we will professionally assist you as indicated in our Term and Conditions. Our expertise includes many years of dealing with complaints (CRP and CHP Australia complaints processes).

More information can be found on our website: [adcheck.com.au](http://adcheck.com.au)



# Setting the industry agenda






# BUILDING TO PEOPLE-LED HEALTHCARE EMPOWERS ALL AUSTRALIANS TOWARDS BETTER HEALTH

People-led healthcare, or self-care, is a modern approach to healthcare that enables all Australians to manage their health confidently. People-led healthcare promotes proactive prevention and management of chronic conditions, and common ailments. It empowers individuals to recognise when they need help from a healthcare professional and enables healthcare providers to offer the necessary care, services, and resources when required.

Unfortunately, current health policy doesn't recognise the role of Australian people in managing their health, nor does it support them in doing so. This gap can be filled by People-led healthcare.

People-led healthcare leads to better health for all. To achieve better health care outcomes, Australians must be empowered to take a more proactive and empowered role in their health and well-being. People-led healthcare can help individuals address their basic needs without barriers and the need for medical advice. In contrast, healthcare providers can focus on highly dependent and acute care requiring specialised skills and knowledge. It allows people to manage their health conditions and everyday health conveniently and successfully at every stage of life when enabled with health literacy, over-the-counter medicines, devices, and preventive care.

## PEOPLE-LED HEALTHCARE



## ADVOCATING FOR INCREASED CONSUMER ACCESS AND BALANCED REGULATION

CHP Australia continued its advocacy in 2022/2023 for greater consumer access to consumer healthcare products and for proportionate, risk-based, regulation.

### We achieved our outcomes by working collaboratively with:



PEAK HEALTHCARE  
PROFESSIONAL BODIES



OTHER INDUSTRY BODIES  
(AUSTRALIAN AND INTERNATIONAL)



MEMBERS



THE TGA



OTHER COMMONWEALTH AND  
STATE GOVERNMENT AGENCIES



ADVERTISERS, BROADCASTERS  
AND PUBLISHERS



PEAK CONSUMER  
BODIES



RESEARCH  
ORGANISATIONS

We have key contacts with 70+ organisations in addition to the Department of Health and Aged Care and the TGA.

In 2022-2023, the focus of government expanded from the Pandemic to also include readiness of supply chains to manage emerging threats and disruptions from the war in Ukraine, potential threats in the Indo-Pacific and threats from increasing weather events due to climate change. The past 12 months saw ongoing progress in relation to switch and S3 Advertising. In terms of our advocacy for a robust supply chain, we continued to focus on manufacturing and sustainability issues by engaging with stakeholders, monitoring the environment, contributing to reforms and keeping members up-to-date on a wide range of issues, including:

- Austrade's Export Market Development Grants
- DISR's Supply Chain Roundtable (SCRT)
- Environmental impacts of medicines
- GMP/Technical Agreements
- Implications to supply due to:
  - Zero Covid lockdowns in China
  - Gas rationing in the EU, particularly Germany
  - Availability of hard wood pallets
  - Australian road freight issues, due to availability of drivers and impacts of extreme weather events.
- IPEF (Indo-Pacific Economic Forum) briefings for industry
- National Packaging Covenant
- PIC/S updates and adoptions
  - With TGA (CM TWG) Preparation of interpretive guidance for listed medicines to support v14
  - TGA Adoption of v 15
  - PIC/S Consultation on introduction of Annex 16
- Product Stewardship Initiatives (e.g. Blister Pack Roundtable and WG)
- Supply Chain Resilience Initiatives – ongoing monitoring
- Simplified Trade System – Project for Streamlining the Cargo intervention Model
- TGA's Medicine Shortages Working Party (MSWP) and Medicines Shortages Section



# Leading on Issues Management

**CHP Australia is the voice of the consumer healthcare products industry with external stakeholders and in the media. CHP Australia advocates for issues important to the industry, promotes the economic and social value of the industry, protects the sector's reputation, and supports consumer education about the responsible use of nonprescription medicines, consumer facing medical devices and self-care.**

CHP Australia continues to build on our advocacy efforts - accommodating shifting policy priorities and adjusting to changes in the political landscape - to ensure members' concerns and issues are being heard in all appropriate forums.

We have seen important outcomes that are important to members, most notably:

- Secured the priority development of the National Health Literacy Strategy, and National Consumer Engagement Strategy for Health and Wellbeing.
- Significantly elevated the role of self-care in the final National Preventive Health Strategy.
- Saw significant self-care principles adopted in the Strengthening Medicare Taskforce Report.
- Introduced the role of self-care in preventive health and health resilience in the ACCI Health Forum: Health Policy Paper.
- Saw the adoption of a range of our industry's election priorities, such as most recently, a review of nicotine vaping products (NVP) advertising permission.
- Further strengthened our engagement and relationship with the Department of Industry, including securing the Industry Minister's participation in our Annual Canberra Stakeholder Summit.
- Led efforts with government and industry stakeholders to address intentional analgesics misuse.
- Ensured specific skills vulnerabilities/shortages affecting the industry were among the handful identified in the Skills Priority List as requiring priority policy attention.
- Contributed non-regulatory insights and feedback to five different Government Departments, Committees and advisory bodies via 9 submissions.
- Sponsored the development of the Life Education's Anti-Vaping Module. This module will be launched this year, for implementation in 2024. CHP Australia will be recognised as sponsors of the program in all advertising material and media.
- We continued to contribute to and promote insightful global and local research, including research that demonstrates the economic, social and health benefits of consumer empowerment in health and the opportunities available through greater self-care.



# Driving Regulatory Reform

CHP Australia continued to influence outcomes at a time of unprecedented regulatory reform. Our work with members, the TGA and other stakeholders drives outcomes that are practical, proportionate, effective and implemented within realistic timeframes.

In the 12 months since July 2022, we had 181 meetings with external stakeholders (including 43 meetings with the TGA). In the same period, we considered 61 regulatory consultations and made submissions in relation to 43. Through our Teams, Working Groups and Subcommittees we discussed reforms and issues with members and agreed on industry positions. Through hundreds of interactions with individual members we explored regulatory complexities and provided support and advice to members.

This close collaboration between the Secretariat, the Members and other stakeholders is what drives our advocacy.



## Advertising

Therapeutic Goods Advertising continues to be a major concern for members. Throughout the year, our advocacy has involved participation in TGA consultations (public and targeted), advice to members, member workshops, meetings with the TGA and meetings with other stakeholders. In particular, our membership of the Therapeutic Goods Advertising Consultative Committee (TGACC) has allowed us to influence discussions and to obtain valuable insights for our members. Key activities include:

- Close liaison with the TGA to project our views
- Close liaison with members to identify issues, to provide solutions and to assist navigating the TGAC and associated guidelines (especially in relation to sampling, testimonials and endorsements)
- Liaison with other stakeholders to socialise the CHP Australia positions
- Detailed responses to public and targeted consultations
- Assisting members with the TGA's complaints processes and sanctions regime
- Ongoing monitoring of emerging advertising issues (e.g. greenwashing)

- CHP Australia's Digital and Social Media Guidelines updated, launched and shared with the TGA
- Key submissions made in relation to:
  - References to TGA in advertising
  - Weight loss products
  - Use of testimonials
  - TGAC guidance
  - TGA's compliance priorities
- CHP Australia feedback incorporated into guidance on Parts 1, 2, and 3 of the TGAC



## TGA's Digital Transformation Program

Through collaboration, feedback and participation, we are working to ensure that the consumer healthcare perspective is being properly incorporated into the TGA's Digital Transformation Project. Key activities included:

- Advancing members' interests
- Receiving regular updates from the TGA and providing to members
- Inclusion as a standing agenda item at Liaison meetings
- Collecting issues to be addressed
- Secretariat and Member feedback to TGA
- Secretariat and member participation on TGA pilots and working groups

- Feedback on various scheduling reforms related to this project (e.g. a searchable Poisons Standard)



## Medical Device Reforms

Throughout the year, we continued to explore opportunities to grow and develop our expertise in relation to Medical Devices and to influence outcomes. Our membership of the TGA's RegTech Forum has allowed us to influence discussions and to obtain valuable insights for our members. Key activities included:

- Membership of, and active participation at, the TGA's RegTech Forum
- Regular meetings of the CHP Australia Devices Team
- Attendance at relevant webinars and seminars
- Participation in public and targeted consultations
- Submissions have been made in relation to:
  - Clinical guidelines
  - Medical Device Vigilance
  - Unique Device Identification
  - Boundary and Combination products
  - MDD to MDR transition
  - Devices incorporating substances





- We have also liaised with ARCS regarding the development of a suitable training course on medical device regulation
- Regarding UDI, the TGA is now likely to adopt a separate approach for devices supplied via retail (consistent with CHP Australia advocacy)
- Regarding the Devices Special Rule 5.5, the TGA is now likely to amend this rule and instead rely on the approval of Comparable Overseas Bodies in support of the safety of the substances (consistent with CHP Australia advocacy)



### Scheduling and Scheduling Environment

Throughout the year we continued to assist members and collaborate with stakeholders to facilitate successful switch applications. We also worked with stakeholders to address obstacles to Appendix M implementation and scheduling issues as they arose. Key activities included:

- NSW Poisons Advisory Committee membership
- Liaison with TGA and pharmacist organisations on Appendix M
- Submissions to ACMS in support of members and down-scheduling generally
- Submissions to ACMS identifying unintended consequences of proposals (e.g. from the TGA's "de-duplication" project)
- Advocating for members in submissions to various targeted and public TGA consultations on scheduling processes (e.g. complex entries, derivatives, etc)
- Major project commenced to align the re-scheduling process with the product registration processes
- IP Working Group re-established (to examine incentives for switch)
- CAS numbers to be incorporated into the Poisons Std (consistent with CHP Australia advocacy)

- Assisted members after scheduling decisions, for example with effective dates, State and Territory labelling exemptions, product applications, etc
- Positive outcomes from the November 2022 decisions on paracetamol mostly consistent with CHP Australia advocacy (e.g. more practical maximum pack sizes, not behind the counter, modified-release products unaffected, no 18yo age limit on purchases) as well as a pragmatic effective date of 1 February 2025
- Monitoring of the NZ classification environment with submissions as appropriate



### Others

We also provided advocacy and member assistance to drive meaningful change across a wide range of other regulatory areas and issues, some of which included:

- APCO packaging projects
- Analgesics and back pain
- Aspartame – classification as a human carcinogen
- Benzophenone and Benzene in sunscreens
- Button batteries
- Cannabis and CBD reforms
- De-duplication of the Poisons Std (vs. 26BB)
- Dextromethorphan (to replace pholcodine)
- Dextromethorphan (safety review and overseas regulatory actions)
- E-leaflets
- Evidence requirements
- Fees and Charges (TGA's "public good" activities to be (partially) funded from consolidated revenue (\$61 million over four years)
- Greenwashing
- IP and switch
- Labelling reforms (e.g. IHIN, Listed medicines' presentation, 26BB and liver warnings)

- Liver toxicity of herbal substances
- Medsafe reforms (e.g. Labelling Statements Database, Medicines Classification Committee decisions)
- National Medicines Policy Review
- Nicotine Vaping Products (e.g. TGA reforms, Government reviews and proposals, restrictions on advertising and flavours, etc)
- Nitrosamines (TGA continuing to follow overseas decisions)
- NSAIDs risks
- NSW Medicines Poisons and Therapeutic Goods Bill (NSW legislation to be brought into line with Commonwealth legislation regarding selling products no longer on the ARTG)
- NZ Therapeutic Products Bill/Act
- Other cough suppressants to replace pholcodine (dihydrocodeine, dextromethorphan)
- Pharmacovigilance Guidance
- Phenylephrine (GRASE status)
- Pholcodine (TGA decision, TGA communications, FOI request)
- Probiotic Medicines – Quality Guidelines
- Product registration following down-scheduling process issues
- Pseudoephedrine (safety review and overseas regulatory actions)
- Real World Data and Real World Evidence
- Recall processes (TGA expected to incorporate CHP Australia feedback on process)
- Scheduling Handbook guidance – Derivatives, CAS number implementation, complex schedule entries
- Sunscreens (e.g. Regulatory Guidelines, Adoption of revised Sunscreen Standards, transition arrangements and impact analysis)
- Sustainability requirements (e.g. APCO targets)
- Sustainability reforms (e.g. blister pack recycling)
- GSCF Sustainability projects



- TGA Review – Safety of Octocrylene and Benzophenone
- Titanium Dioxide restrictions (TGA awaiting FSANZ review and noting that other regulators are not agreeing with EFSA's review outcome)
- Triptan re-scheduling and registrations
- Vitamin D (risks and benefits)



### Emerging issues

CHP Australia's secretariat are able to keep members up-to-date through our:

- Membership of GSCF Working Groups and Subcommittees

- Close collaboration with sister organisations such as AESGP, CHPA, CHPNZ, FHCP and PAGB
- Regular contact and liaison with more than 70 Australian organisations and government departments
- Environmental monitoring
- Issuing ALERTs and FYIs to members
- Liaising with members individually and collectively



# Sustainability at CHP Australia

During the 2022-23 year, CHP Australia has continued to expand our role in Sustainability.

In September 2022, we provided our Board endorsed environmental sustainability pledge to support the work of GSCF and their charter for environmentally sustainable self-care. GSCF identified 3 areas of focus – packaging, pharmaceuticals in the environment, and CO2 footprint. CHP Australia has pledged actions to address each area of the charter, however our primary focus, informed by our Sustainability Subcommittee, has been to increase work to support

members in meeting the APCO 2025 National Packaging Targets.

A high area of interest for members has been to explore the development of recycling opportunities to support difficult to recycle packaging materials, with an initial focus on blister tray collection and recycling. Recognising that blister trays are an industry-wide challenge, in April 2023, CHP Australia convened the first industry roundtable on blister pack recycling, gathering together representatives from across the medicines industries and supply chains, with product stewardship and recycling experts, to explore

opportunities to address this challenge as a collective. Representatives agreed that this is an important piece of work for the industry, and agreed to form a Blister Pack Industry Working Group, which has been progressing the action points identified at the roundtable. CHP Australia has been leading this project, however it is the ongoing involvement and commitment of the whole of industry that will be pivotal in the success of the project to be able to divert this important form of packaging from landfill and into a circular economy model.







CHP Australia has proudly continued to sponsor Life Education’s “Mind your Medicines” curriculum module, promoting self-care and health literacy among Australian students, teachers, and parents.

This year, we also sponsored the development of an anti-vaping module for Stage 3 (year 5 and 6) students. The module is engaging and informative, featuring visual content that was built by high school students, featuring primary school students, and guided by educators and education specialists. To support educators, Life Education has also created support resources for teachers and parents to continue the conversation outside of Life Education’s content delivery.



We have continued the very successful collaboration with the Sydney North Health Network (SNHN), including sponsorship of their GPs in High Schools program and Preventive Health Symposium.

Through our partnership with SNHN, the GPs in Schools program reached 4,000 – 5,000 students at approximately 30 schools, visited by 80 GPs and nurses with the involvement of approximately 100 teachers/school psychologists. Together with SNHN, we strive to reach ALL Year 11 students, aged 16 – 17 as they transition into adulthood, in the SNHN region and in the longer term to extend the program to other regions throughout NSW and Australia.



THE UNIVERSITY OF  
**NEWCASTLE**  
AUSTRALIA

CHP Australia has engaged the University of Newcastle to develop a local model for community pharmacies to enhance consumer self-care behaviour using digital information.

The University will partner with local providers to co-design a sustainable model to promote and support consumers’ self-care behaviours through using existing digital health information and resources.

Trials regarding this work are currently underway and expected to be complete in 2025.



In addition to contributing to various consultations and meetings, CHP Australia has proudly endorsed the Australian Self-Care Alliance’s Self-Care Charter, which promotes self-care to policy-makers, healthcare professionals and consumers. The Self-Care Charter identifies that in order to practice good self-care, consumers need:

- Knowledge,
- Access,
- Choices,
- Opportunity,
- A National Self-Care Strategy,
- E-Health technologies,
- Low-Cost care,
- Healthcare workers,
- Services working together, and
- Research



CHP Australia has been actively supporting GSCF’s objectives to:

- achieve a WHO resolution on self-care by 2025
- promote the benefit and value of self-care interventions for stakeholders
- support members on global issues and opportunities around regulatory, safety, and policy affairs
- lead and support environmental sustainability in self-care.

CHP Australia has been actively engaging on various working groups including the Environmental Sustainability Working Group, Regulatory Affairs Committee, Communications and Public Affairs Committee and Policy Committee, as well as individual ingredient issues and campaigns on the WHO resolution.



## CHP Australia Board



**Dr. Aniss Chami**  
Vitex Pharmaceuticals



**Sylvain Vigneault**  
Viartis



**Alison Holland**  
Aspen Pharmacare



**Andrew Jenkin**  
iNova Pharmaceuticals  
(Vice-Chair)



**Phil Lynch**  
Chair



**Jonas Marques**  
Bayer  
(ceased 27/07/2023)



**Alan Oppenheim**  
Ego Pharmaceuticals



**Anish Patel**  
Haleon



**David Rankine**  
Reckitt  
(ceased 31/07/2023)



**Nadia Stone**  
Kenvue

## CHP Australia Board Composition

The CHP Australia Board composition, nomination, elections and executive roles are all governed by the CHP Australia Constitution.

The CHP Australia Board consists of up to ten Directors as follows:

- Up to six Directors elected from the Official Delegates of the CHP Australia Ordinary Members (Elected Directors)
- Up to four Directors appointed by the Board (Skills-based Directors)

The Elected Directors each hold office for two years and every year three of the Elected Directors retire from the Board. In advance of each annual retirement, CHP Australia calls for expressions of interest and holds elections for

the three Director positions to be vacated. This ensures that there are opportunities for new Directors while maintaining continuity of expertise.

While each Elected Director must be the Official Delegate of an Ordinary Member, the Skills-based Directors can be drawn from a much wider set of candidates (including, for example, Honorary Life Members, Associate Members and non-members).

The CHP Australia Elected Directors as at 30 June 2023:

- **Aniss Chami**, Vitex Pharmaceuticals
- **Alison Holland**, Aspen Pharmacare
- **Andrew Jenkin**, iNova Pharmaceuticals (Vice Chair)

- **Alan Oppenheim**, Ego Pharmaceuticals
- **Anish Patel**, Haleon
- **Nadia Stone**, Kenvue

The CHP Australia Skills-based Directors as at 30 June 2022:

- **Phil Lynch** (Chair)
- **Sylvain Vigneault**, Viartis
- **Jonas Marques**, Bayer
- **David Rankine**, Reckitt

There are currently two Skills based Director vacancies due to the resignations of Jonas Marques, Bayer, and David Rankine, Reckitt.



# CHP Australia Members

## Ordinary Members (at time of printing)



## Associate Members (at time of printing)



# Subcommittees and Working Groups


CHP Australia subcommittees and working groups provide you with the opportunity to be directly involved with CHP Australia’s work programme and help deliver our strategic plan. Members of these groups meet regularly to plan activities and guide how we shape the regulatory environment, advocate on key issues and provide member services and engagement.

This gives members the opportunity to:

- Contribute to the CHP Australia position on key issues
- Shape industry work
- Keep up to date with current issues
- Meet with the TGA

We greatly value the involvement of our subcommittees and working group members and would like to thank all members who give their time to achieve our shared goals.


**For more information on how to get involved email us at [info@chpaustralia.com.au](mailto:info@chpaustralia.com.au)**





# CHP Australia – Your Support Team

## CHP AUSTRALIA SECRETARIAT



## ADCHECK SERVICE



**Kevin Christopher**  
Advertising Compliance Manager



**Josie Braid**  
Advertising Compliance Senior Consultant



**Leenus Mariathas**  
Advertising Compliance Senior Consultant



**Emily Ma**  
Advertising Compliance Consultant



**Neranyia Naidoo**  
Advertising Compliance Consultant

### WE'RE HERE TO HELP

**General Enquiries:**

Suite 1, Level 2  
35 Chandos St  
St Leonards NSW 2065

Ph: +61 2 9922 5111  
info@chpaustralia.com.au

**AdCheck Enquiries:**

Ph: +61 2 9922 5111  
adcheck@chpaustralia.com.au

# CHP Australia Events

## Webinars

---

**26 July 2022** Launching the Self-Care Opportunity Research Paper

**25 August 2022** What we Really ask Dr Google – Healthcare Insights in the Digital Age

**13 October 2022** CHP Australia Digital/Social Media Guidelines Virtual Launch

**3 November 2022** Australasian Recycling Label discussion with the National Retail Association & APCO

**8 March 2023** The evolving privacy landscape - building trust in uncertain times with Gadens

**5 April 2023** Updates to Sunscreens Regulation

**21 June 2023** Chat GPT: Friend or Foe with Vine Digital

**6 July 2023** Award Entry Guidance & Critical Tools in a Marketing Plan with Xpotential

**16 August 2023** Exports in a post-covid world with Peter Osborne, 6AM Agency

## TGAC Workshop

---

**17, 24 & 31 August 2022** Therapeutic Goods Advertising Code (TGAC) – Workshop (Virtual)

**12, 19 & 26 October 2022** Therapeutic Goods Advertising Code (TGAC) – Workshop (Virtual)

**8, 15 & 22 February 2023** Therapeutic Goods Advertising Code (TGAC) – Workshop (Virtual)

**15 March 2023** Therapeutic Goods Advertising Code (TGAC) – 1 Day Workshop (Face-to-Face)

**12, 19 & 26 April 2023** Therapeutic Goods Advertising Code (TGAC) – Workshop (Virtual)

**17-May Sydney 2023** Therapeutic Goods Advertising Code (TGAC) - Workshop (Face-to-Face)

**14, 21 & 28 June 2023** Therapeutic Goods Advertising Code (TGAC) – Workshop (Virtual)

**16, 23 & 30 August 2023** Therapeutic Goods Advertising Code (TGAC) – Workshop (Virtual)

## AGM

---

**17 November 2022**

## Self-Care Excellence Awards

---

**23 November 2022**

## Member Forum

---

**17 November 2022** Cyber Security in Australia with Dr Derek Bopping and IQVIA

**28 April 2023** Consumer Insights with Circana, Edelman & IQVIA

## External Engagement

---

**30 March 2023** Canberra Stakeholder Summit

**21 April 2023** Industry Blister Pack Recycling Roundtable

# CHP Australia Member Services



## Advice and Support

- Pool of expertise to utilise
- Confidential advice on regulatory, technical, marketing and media management issues
- Member workshops to navigate current/pending regulatory reforms



## Advocacy and Representation

- “Voice of industry” on issues impacting industry, segments, ingredients
- Member conduit to media, stakeholders, government, TGA
- Parliamentary Events
- Strength in numbers



## Shaping Industry Initiatives

- Committee, working group involvement
- Share experiences with other members
- Contribute to the CHP Australia position/shape industry work



## Staying informed

- Keep up to date on issues
- Local and international monitoring of issues with briefs and alerts to members
- E-newsletters, alerts, events, seminars, workshops, web portal



## Self Regulation

- CHP Australia Code
- CHP Australia Complaints Panel



## Member Events

- World Class Industry Events
- Education Seminars
- Member Forums
- CHP Australia’s Conference and Self-Care Excellence Awards



## Member Training

- In house training and inductions
- Therapeutic Goods Advertising Training
- Member workshops



## **GENERAL ENQUIRIES**

Suite 1, Level 2  
35 Chandos St,  
St Leonards NSW 2065

**Ph: +61 2 9922 5111**

info@chpaustralia.com.au  
www.chpaustralia.com.au  
ABN 55 082 798 952

---

## **MEMBERSHIP ENQUIRIES**

Membership Services Manager  
CHP Australia

**Ph: +61 2 9059 2439**

---

## **ADCHECK ENQUIRIES**

**Ph: +61 2 9922 5111**  
adcheck@chpaustralia.com.au

---

## **MEDIA ENQUIRIES**

Public Affairs Manager

**Ph: +61 2 9059 2442**  
media@chpaustralia.com.au

**chpaustralia.com.au**



**Consumer Healthcare  
Products Australia**

**Advancing Responsible Self-Care**